<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### [Editorial (Sep 21)](/page/updates/#a.sars-cov-2.antiviral.therapy.score.card.sep.21.)

Shafer R. ‚ÄúA SARS-CoV-2 antiviral therapy score card‚Äù _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

### [New clinical trials (Sep 18)](/page/updates/#new.clinical.trials.sep.18.)

13 clinical trials were added since September 17: [list of new clinical trials](/clinical-trials/?fromDate=2020-09-17).

### [Published preprints (Sep 18)](/page/updates/#published.preprints.sep.16.sep.18.)

Lokugamage KG, etc. [‚ÄúType I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.‚Äù](/search/?article=Lokugamage20) _Journal of Virology_, 2020. [doi.org/10.1128/jvi.01410-20](https://doi.org/10.1128/jvi.01410-20). [PubMed32938761](https://www.ncbi.nlm.nih.gov/pubmed/32938761/)

### [Published preprints (Sep 15)](/page/updates/#published.preprints.sep.16.sep.18.)

Liu STH, etc. [‚ÄúConvalescent plasma treatment of severe COVID-19: a propensity score‚Äìmatched control study.‚Äù](/search/?article=Liu20d) _Nature Medicine_, 2020. [doi.org/10.1038/s41591-020-1088-9](https://doi.org/10.1038/s41591-020-1088-9). [PubMed32934372](https://www.ncbi.nlm.nih.gov/pubmed/32934372/).

### [Newly added reference (Sep 15)](/page/updates/#newly.added.reference.sep.15.)

Li T, Han X, et int., and Jin A. [‚ÄúA key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.‚Äù](/search/?article=Li20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
